In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations

• Published in: Neuropsychiatric disease and treatment 2022-01, Vol.18, p.2497-2506
• Main Authors: Tan, Laura A, Gajipara, Nileshkumar, Sun, Lei, Bacolod, Maria, Zhou, Ying, Namchuk, Mark, Cunningham, Jacobi I
• Format: Article
• Language: English
• Subjects: alks 3831; Antipsychotics; Bipolar disorder; bipolar i disorder; Brain; Cardiovascular disease; Chemical properties; Chromatography; Complications and side effects; Drug therapy; Humidity; Laboratory animals; Ligand binding (Biochemistry); Liquid chromatography; lybalvi; Mass spectrometry; Mass spectroscopy; Mental disorders; Metabolism; Naltrexone; Narcotic antagonists; Narcotics; Olanzapine; opioid receptor; Opioid receptors (type delta); Opioid receptors (type kappa); Opioid receptors (type mu); Opioids; Original Research; Particle size; Pharmacokinetics; Pharmacology, Experimental; Physiological aspects; Plasma; Psychotropic drugs; Receptors; Rodents; Schizophrenia; Scientific imaging
• ISSN: 1178-2021; 1176-6328; 1178-2021
• DOI: 10.2147/NDT.S373195

Introduction: The atypical antipsychotic olanzapine is approved for the treatment of schizophrenia and bipolar I disorder; however, weight gain and metabolic dysregulation associated with olanzapine therapy have limited its clinical utility. In clinical studies, treatment with the combination of olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM) mitigated olanzapine-associated weight gain while providing antipsychotic efficacy similar to that of olanzapine. Although samidorphan is structurally similar to the opioid receptor antagonist naltrexone, the two differ in their pharmacokinetics and in vitro binding affinities to mu, delta, and kappa opioid receptors (MOR, DOR, and KOR, respectively). The objective of this series of nonclinical studies was to compare the in vivo binding profiles of samidorphan and naltrexone and their receptor occupancies at MOR, DOR, and KOR in rat brains. Methods: Male rats were injected with samidorphan or naltrexone to obtain total and unbound plasma and brain concentrations representing levels observed in humans at clinically relevant oral doses. Subsequently, samidorphan and naltrexone brain receptor occupancy at MOR, DOR, and KOR was measured using ultra-performance liquid chromatography and high-resolution accurate-mass mass spectrometry. Results: A dose-dependent increase in samidorphan occupancy was observed at MOR, DOR, and KOR ([EC.sub.50]: 5.1, 54.7, and 42.9 nM, respectively). Occupancy of naltrexone at MOR ([EC.sub.50]: 15.5 nM) and KOR was dose dependent; minimal DOR occupancy was detected. At the clinically relevant unbound brain concentration of 23.1 nM, samidorphan bound to MOR, DOR, and KOR with 93.2%, 36.1%, and 41.9% occupancy, respectively. At 33.5 nM, naltrexone bound to MOR and KOR with 79.4% and 9.4% occupancy, respectively, with no binding at DOR. Discussion: At clinically relevant concentrations, samidorphan occupied MOR, DOR, and KOR, whereas naltrexone occupied only MOR and KOR. The binding profile of samidorphan differs from that of naltrexone, with potential clinical implications. Keywords: ALKS 3831, bipolar I disorder, Lybalvi, olanzapine, opioid receptor, schizophrenia